Insider · CIK 0001669866

Garcia Marino

Reports to the SEC for 3 companies · ANTWERPEN

sec.gov

Transactions

Companies

Filings

CIK

0001669866

Forms 4 and 5

Insider transactions

29 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-11	AGMBAgomAb Therapeutics NV · Stock Option (Right to Buy)A Award	Director	AAward	+57.5K sh	—	—	57,482
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	−126K sh	—	—	160,004
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	−40K sh	—	—	286,004
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−21.9K sh	$108.72	−$2.38M	65,292
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−104K sh	$107.96	−$11.2M	87,102
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	+40K sh	$8.44	+$338K	105,292
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	+126K sh	$8.44	+$1.06M	231,292
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−10.4K sh	$107.49	−$1.12M	220,908
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−23.9K sh	$108.05	−$2.58M	197,001
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−2,373 sh	$109.10	−$259K	194,628
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−2,536 sh	$110.02	−$279K	192,092
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−800 sh	$110.76	−$88.6K	191,292
2026-03-16	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	+59.7K sh	$6.70	+$400K	59,700
2026-03-16	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	+5,592 sh	$17.88	+$100K	65,292
2026-03-16	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	−59.7K sh	—	—	41
2026-03-16	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	−5,592 sh	—	—	269,408
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	+123K sh	$6.70	+$824K	122,918
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−43.5K sh	$80.69	−$3.51M	79,413
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−65.5K sh	$81.74	−$5.36M	13,896
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−12.8K sh	$82.60	−$1.06M	1,100
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−200 sh	$83.38	−$16.7K	900
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director, CEO AND PRESIDENT	SSale	−900 sh	$85.53	−$77K	0
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO AND PRESIDENT	MExercise/Conversion	−123K sh	—	—	59,741
2026-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director, CEO AND PRESIDENT	AAward	+355K sh	—	—	355,000
2025-09-30	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director, CEO AND PRESIDENT	AAward	+120K sh	—	—	120,000
2025-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director, CEO AND PRESIDENT	AAward	+340K sh	—	—	340,000
2024-05-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director, CEO AND PRESIDENT	AAward	+243K sh	—	—	243,000
2024-01-24	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director, CEO AND PRESIDENT	AAward	+275K sh	—	—	275,000
2016-06-24	SYNERGY PHARMACEUTICALS LLCStock OptionsA Award	EVP and Chief Strategy Officer	AAward	+200K sh	—	—	730,000

Recent filings

Accepted (ET)
Sep 154
Garcia Marino0001104659-26-107916
SEC(opens sec.gov)
Aug 74
Garcia Marino0001669866-26-000010
SEC(opens sec.gov)
Mar 174
Garcia Marino0001669866-26-000007
SEC(opens sec.gov)
Mar 134
Garcia Marino0001669866-26-000005
SEC(opens sec.gov)

Companies

Address

AGOMAB THERAPEUTICS NV POSTHOFLEI 1/6

ANTWERPEN, 2600